| Metric | Current Period | Prior-Year Period | YoY |
|---|---|---|---|
| Revenue | ¥104.4B | ¥91.6B | +14.0% |
| Operating Income | ¥6.8B | ¥4.3B | +56.5% |
| Ordinary Income | ¥6.3B | ¥3.7B | +70.6% |
| Net Income | ¥4.3B | ¥2.9B | +50.7% |
| ROE | 14.4% | 10.2% | - |
Cumulative results for FY2026 Q3 delivered higher revenue and profits: Revenue ¥104.4B (from ¥91.6B in the same period of the prior year, +¥12.8B, +14.0%), Operating Income ¥6.8B (from ¥4.3B, +¥2.5B, +56.5%), Ordinary Income ¥6.3B (from ¥3.7B, +¥2.6B, +70.6%), and Net Income ¥4.3B (from ¥2.9B, +¥1.4B, +50.7%). In addition to double-digit top-line growth, operating leverage lifted the operating margin to 6.5% (from 4.7% a year ago, +1.8pt), markedly improving profitability. However, an impairment loss of ¥0.9B and a gain on sale of shares of a subsidiary of ¥0.4B were recognized, indicating the profit mix includes non-recurring items.
[Profitability] ROE 14.4% (above the industry median of 9.7%), Operating Margin 6.5% (from 4.7% a year ago, +1.8pt), Net Margin 4.1% (from 3.1% a year ago, +1.0pt), Return on Assets 4.0%. DuPont decomposition of ROE: Net Margin 4.1%, Asset Turnover 0.971x, Financial Leverage 3.59x. Tax burden coefficient 0.691, interest burden coefficient 0.923. Interest Coverage 11.78x, indicating ample capacity to service interest.
[Cash Quality] Cash and Deposits ¥16.3B (down from ¥23.5B a year ago, -30.7%), Short-term Debt Coverage 1.78x (Cash and Deposits/Short-term Borrowings).
[Investment Efficiency] Asset Turnover 0.971x.
[Financial Soundness] Equity Ratio 27.8% (from 22.6% a year ago, +5.2pt), Current Ratio 125.8%, Debt-to-Equity Ratio 2.59x, Interest-bearing debt ¥52.9B, Debt/Capital ratio 63.9%.
Cash and Deposits decreased by ¥7.2B from ¥23.5B in the prior-year period to ¥16.3B (-30.7%), indicating a contraction in liquidity. Meanwhile, Retained Earnings increased by ¥4.3B from ¥5.9B to ¥10.2B (+73.3%), reflecting that Net Income of ¥4.3B fed into internal reserves. In working capital efficiency, Accounts Receivable declined substantially from ¥16.97B to ¥11.71B (-¥5.3B, -31.0%), showing strong progress in collections. Accounts Payable increased from ¥6.4B to ¥7.2B (+¥0.8B, +12.1%), suggesting appropriate management of payment terms. Short-term Borrowings remained flat at ¥9.1B, and of the ¥43.8B in Long-term Borrowings, ¥12.5B is scheduled for repayment within one year, necessitating repayment or refinancing over the next 12 months under the cash management plan. Cash and Deposits are 1.78x Short-term Borrowings, and cash coverage of total current liabilities is 0.78x; while short-term liquidity is secured, the decline in cash likely reflects deployment toward working capital improvement, capital expenditures, and debt repayment.
Against Ordinary Income of ¥6.3B, Operating Income was ¥6.8B, implying net non-operating expenses of approximately ¥0.5B due to interest burden and foreign exchange gains/losses. Detailed disclosure of non-operating income is limited, but interest expense of ¥0.6B was recorded; the interest burden on Interest-bearing debt of ¥52.9B is around 1.1%. In extraordinary gains and losses, an impairment loss of ¥0.9B and a gain on sale of shares of a subsidiary of ¥0.4B were recognized, meaning roughly ¥0.5B of the ¥4.3B in Net Income stems from non-recurring items. The impairment is presumed to be a one-off treatment of underperforming assets, and the gain on sale likely reflects business reorganization; excluding these, the recurring earnings power on an operating basis is estimated at roughly 90% of reported Net Income. As evidenced by the substantial reduction in Accounts Receivable (-31.0%), working capital has improved, and accounting earnings are aligned with cash inflows; however, the decline in Cash and Deposits indicates that cash outflows for investment or financing exceeded collections.
[Positioning within the Industry] (Reference information, our estimates) Profitability: Operating Margin 6.5% (1.7pt below the industry median of 8.2%), Net Margin 4.1% (1.6pt below the industry median of 5.7%), ROE 14.4% (4.7pt above the industry median of 9.7%), Return on Assets 4.0% (0.7pt below the industry median of 4.7%). Profitability trails the industry median on operating and net margins, but ROE significantly exceeds the median due to financial leverage. Soundness: Equity Ratio 27.8% (21.2pt below the industry median of 49.0%), Current Ratio 125.8% (well below the industry median of 206%), and Net Debt/EBITDA is positive; compared with the industry median of -1.75x, reliance on debt is markedly higher. Financial soundness ranks in the lower tier of the industry, with substantial room to improve capital structure. Growth: Revenue growth rate 14.0% (+4.5pt above the industry median of 9.5%), placing the company among the faster growers in the industry. While top-line expansion is steady, the balance between growth and margins, and consistency with cash flow, will be key evaluation points. Industry: Healthcare (N=44 companies), Comparison period: 2025-Q3 reporting, Source: Our compilation
Key takeaways are as follows. First, the 14.0% Revenue growth rate and 56.5% Operating Income growth rate highlight the effect of operating leverage, confirming cost structure efficiencies during a sales expansion phase. Selling, general and administrative expense growth lagged revenue growth versus the prior year, improving Operating Margin by 1.8pt and suggesting a better earnings structure. Second, the duality in financial structure: ROE of 14.4% is well above the industry median, indicating strong shareholder capital efficiency; however, this is underpinned by high leverage with a Debt-to-Equity Ratio of 2.59x, while the Equity Ratio of 27.8% is well below the industry median of 49.0%. High leverage amplifies shareholder returns in upcycles but increases downside risk in adverse environments. Third, the divergence between working capital management and cash trends: while the large collection of receivables (-31.0%) indicates improved working capital efficiency, Cash and Deposits declined -30.7% over the same period. This divergence suggests collected funds were likely allocated to capital expenditures and debt repayment, necessitating verification of Free Cash Flow generation capacity. Progress against the full-year plan stands at 72.5% for revenue and 90.1% for operating income; revenue is tracking ahead of plan, but profit is broadly in line, implying limited room for incremental profit build in Q4.
This report is an automatically generated earnings analysis created by AI based on XBRL financial summary data. It does not constitute a recommendation to invest in any specific security. The industry benchmarks are reference information compiled by us from publicly available financial statements. Investment decisions are your own responsibility; consult a professional as needed before making any decisions.